CHM 0201
Alternative Names: CHM-0201Latest Information Update: 12 Jan 2024
At a glance
- Originator Chimeric Therapeutics
- Developer Case Western Reserve University; Chimeric Therapeutics; M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; Colorectal cancer
Most Recent Events
- 28 Nov 2023 Phase-I clinical trials in Acute myeloid leukaemia (Combination therapy) in USA (IV) (Chimeric Therapeutics pipeline; November 2023)
- 28 Nov 2023 Phase-I clinical trials in Colorectal cancer (Combination therapy) in USA (IV) (Chimeric Therapeutics pipeline; November 2023)
- 28 Nov 2023 Chimeric Therapeutics completes Phase-IA/B trial in Acute myeloid leukaemia and Colorectal cancer in USA (IV) (Chimeric Therapeutics pipeline; November 2023)